ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Stock Competitors & Peer Comparison
See ACAD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ACAD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACAD | $28.74 | +1.27% | 4.8B | 13.71 | $2.06 | N/A |
| VRTX | $517.38 | +0.18% | 128.4B | 26.58 | $19.03 | N/A |
| REGN | $807.53 | +0.19% | 82.8B | 17.61 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $991.15 | +15.66% | 52.9B | 76.83 | $11.08 | N/A |
| RVMDW | $12.40 | +11.71% | 44B | -1.55 | -$7.21 | N/A |
| RVMD | $215.12 | +6.50% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $360.47 | +1.25% | 37.1B | 61.18 | $5.68 | N/A |
| ALNY | $224.31 | -1.24% | 30.6B | 41.20 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ACAD vs VRTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, VRTX has a market cap of 128.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while VRTX trades at $517.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas VRTX's P/E ratio is 26.58. In terms of profitability, ACAD's ROE is +0.32%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ACAD is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ACAD vs REGN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, REGN has a market cap of 82.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while REGN trades at $807.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas REGN's P/E ratio is 17.61. In terms of profitability, ACAD's ROE is +0.32%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ACAD is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ACAD vs VRNA Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ACAD's ROE is +0.32%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ACAD is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ACAD vs ARGX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ARGX has a market cap of 52.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ARGX trades at $991.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ARGX's P/E ratio is 76.83. In terms of profitability, ACAD's ROE is +0.32%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ACAD is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ACAD vs RVMDW Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RVMDW has a market cap of 44B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RVMDW trades at $12.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RVMDW's P/E ratio is -1.55. In terms of profitability, ACAD's ROE is +0.32%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ACAD is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ACAD vs RVMD Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RVMD trades at $215.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RVMD's P/E ratio is -23.10. In terms of profitability, ACAD's ROE is +0.32%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ACAD is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
ACAD vs SGEN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ACAD's ROE is +0.32%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ACAD is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
ACAD vs ONC Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ONC has a market cap of 37.1B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ONC trades at $360.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ONC's P/E ratio is 61.18. In terms of profitability, ACAD's ROE is +0.32%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ACAD is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ACAD vs ALNY Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ALNY trades at $224.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ALNY's P/E ratio is 41.20. In terms of profitability, ACAD's ROE is +0.32%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ACAD is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
ACAD vs INSM Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, INSM has a market cap of 26.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while INSM trades at $127.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas INSM's P/E ratio is -27.08. In terms of profitability, ACAD's ROE is +0.32%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ACAD is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ACAD vs ROIV Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ROIV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ROIV's P/E ratio is -34.44. In terms of profitability, ACAD's ROE is +0.32%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ACAD is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ROIV's competition here
Moderna, Inc. (NASDAQ: MRNA)
ACAD vs MRNA Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MRNA has a market cap of 25.1B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MRNA trades at $64.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MRNA's P/E ratio is -7.77. In terms of profitability, ACAD's ROE is +0.32%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ACAD is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check MRNA's competition here
Incyte Corporation (NASDAQ: INCY)
ACAD vs INCY Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while INCY trades at $123.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas INCY's P/E ratio is 16.15. In terms of profitability, ACAD's ROE is +0.32%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ACAD is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ACAD vs BNTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, BNTX has a market cap of 23.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while BNTX trades at $91.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas BNTX's P/E ratio is -16.84. In terms of profitability, ACAD's ROE is +0.32%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ACAD is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ACAD vs UTHR Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, UTHR has a market cap of 21.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while UTHR trades at $504.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas UTHR's P/E ratio is 17.88. In terms of profitability, ACAD's ROE is +0.32%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ACAD is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ACAD vs BGNE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ACAD's ROE is +0.32%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ACAD is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
ACAD vs GMAB Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, GMAB has a market cap of 19.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while GMAB trades at $32.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas GMAB's P/E ratio is 24.07. In terms of profitability, ACAD's ROE is +0.32%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ACAD is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ACAD vs DNA-WT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ACAD's ROE is +0.32%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ACAD is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ACAD vs BBIO Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, BBIO has a market cap of 15.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while BBIO trades at $79.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas BBIO's P/E ratio is -21.35. In terms of profitability, ACAD's ROE is +0.32%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ACAD is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ACAD vs ASND Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ASND has a market cap of 15.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ASND trades at $247.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ASND's P/E ratio is -102.69. In terms of profitability, ACAD's ROE is +0.32%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ACAD is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ACAD vs JAZZ Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while JAZZ trades at $247.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas JAZZ's P/E ratio is 9.13. In terms of profitability, ACAD's ROE is +0.32%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ACAD is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ACAD vs NBIX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while NBIX trades at $153.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas NBIX's P/E ratio is 22.07. In terms of profitability, ACAD's ROE is +0.32%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ACAD is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check NBIX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ACAD vs BMRN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, BMRN has a market cap of 13B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while BMRN trades at $66.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas BMRN's P/E ratio is 32.38. In terms of profitability, ACAD's ROE is +0.32%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ACAD is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check BMRN's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ACAD vs EXEL Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while EXEL trades at $52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas EXEL's P/E ratio is 14.64. In terms of profitability, ACAD's ROE is +0.32%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ACAD is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ACAD vs KRTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ACAD's ROE is +0.32%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ACAD is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ACAD vs ARWR Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ARWR trades at $88.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ARWR's P/E ratio is -38.51. In terms of profitability, ACAD's ROE is +0.32%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ACAD is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ACAD vs MDGL Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MDGL trades at $513.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MDGL's P/E ratio is -39.65. In terms of profitability, ACAD's ROE is +0.32%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ACAD is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check MDGL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ACAD vs HALO Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, HALO has a market cap of 11.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while HALO trades at $103.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas HALO's P/E ratio is 18.41. In terms of profitability, ACAD's ROE is +0.32%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ACAD is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ACAD vs TECH Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while TECH trades at $72.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas TECH's P/E ratio is 37.32. In terms of profitability, ACAD's ROE is +0.32%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ACAD is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ACAD vs RNAM Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ACAD's ROE is +0.32%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ACAD is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ACAD vs AXSM Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, AXSM has a market cap of 11B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while AXSM trades at $215.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas AXSM's P/E ratio is -55.79. In terms of profitability, ACAD's ROE is +0.32%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ACAD is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ACAD vs SMMT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while SMMT trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas SMMT's P/E ratio is -8.34. In terms of profitability, ACAD's ROE is +0.32%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ACAD is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check SMMT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ACAD vs PRAX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, PRAX has a market cap of 10.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while PRAX trades at $374.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas PRAX's P/E ratio is -28.37. In terms of profitability, ACAD's ROE is +0.32%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ACAD is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ACAD vs PTGX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while PTGX trades at $157.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas PTGX's P/E ratio is 150.58. In terms of profitability, ACAD's ROE is +0.32%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ACAD is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check PTGX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ACAD vs KRYS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while KRYS trades at $335.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas KRYS's P/E ratio is 41.64. In terms of profitability, ACAD's ROE is +0.32%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ACAD is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ACAD vs KYMR Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while KYMR trades at $121.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas KYMR's P/E ratio is -36.68. In terms of profitability, ACAD's ROE is +0.32%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ACAD is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ACAD vs RXDX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ACAD's ROE is +0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ACAD is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ACAD vs IONS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, IONS has a market cap of 9.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while IONS trades at $58.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas IONS's P/E ratio is -33.28. In terms of profitability, ACAD's ROE is +0.32%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ACAD is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ACAD vs CYTK Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CYTK has a market cap of 9.1B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CYTK trades at $74.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CYTK's P/E ratio is -11.83. In terms of profitability, ACAD's ROE is +0.32%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ACAD is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ACAD vs NUVL Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ACAD's ROE is +0.32%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ACAD is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check NUVL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ACAD vs SYRE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, SYRE has a market cap of 9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while SYRE trades at $104.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas SYRE's P/E ratio is -53.14. In terms of profitability, ACAD's ROE is +0.32%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ACAD is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check SYRE's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ACAD vs CRNX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CRNX trades at $84.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CRNX's P/E ratio is -16.81. In terms of profitability, ACAD's ROE is +0.32%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ACAD is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
ACAD vs ABVX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ABVX trades at $121.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ABVX's P/E ratio is -62.36. In terms of profitability, ACAD's ROE is +0.32%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ACAD is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ACAD vs IMGN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ACAD's ROE is +0.32%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ACAD is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check IMGN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ACAD vs IMVT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, IMVT has a market cap of 8.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while IMVT trades at $43.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas IMVT's P/E ratio is -14.83. In terms of profitability, ACAD's ROE is +0.32%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ACAD is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ACAD vs PCVX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while PCVX trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas PCVX's P/E ratio is -7.61. In terms of profitability, ACAD's ROE is +0.32%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ACAD is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ACAD vs BPMC Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ACAD's ROE is +0.32%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ACAD is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ACAD vs APGE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while APGE trades at $134.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas APGE's P/E ratio is -31.07. In terms of profitability, ACAD's ROE is +0.32%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ACAD is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
ACAD vs ALKS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ALKS trades at $49.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ALKS's P/E ratio is 51.64. In terms of profitability, ACAD's ROE is +0.32%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ACAD is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ACAD vs CERE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CERE's P/E ratio is -16.47. In terms of profitability, ACAD's ROE is +0.32%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ACAD is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ACAD vs IBRX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while IBRX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas IBRX's P/E ratio is -7.80. In terms of profitability, ACAD's ROE is +0.32%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ACAD is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ACAD vs RYTM Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RYTM trades at $115.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RYTM's P/E ratio is -37.13. In terms of profitability, ACAD's ROE is +0.32%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ACAD is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ACAD vs TGTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while TGTX trades at $49.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas TGTX's P/E ratio is 17.66. In terms of profitability, ACAD's ROE is +0.32%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ACAD is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ACAD vs MTSR Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ACAD's ROE is +0.32%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ACAD is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
ACAD vs MRUS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ACAD's ROE is +0.32%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ACAD is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ACAD vs ACLX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ACAD's ROE is +0.32%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ACAD is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check ACLX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ACAD vs ORKA Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ORKA has a market cap of 6.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ORKA trades at $111.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ORKA's P/E ratio is -57.24. In terms of profitability, ACAD's ROE is +0.32%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ACAD is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
ACAD vs CGON Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CGON trades at $76.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CGON's P/E ratio is -27.89. In terms of profitability, ACAD's ROE is +0.32%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ACAD is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ACAD vs RETA Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RETA's P/E ratio is -66.29. In terms of profitability, ACAD's ROE is +0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ACAD is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ACAD vs BLTE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while BLTE trades at $162.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas BLTE's P/E ratio is -87.06. In terms of profitability, ACAD's ROE is +0.32%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ACAD is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check BLTE's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ACAD vs DNTH Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, DNTH has a market cap of 6.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while DNTH trades at $114.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas DNTH's P/E ratio is -27.94. In terms of profitability, ACAD's ROE is +0.32%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ACAD is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ACAD vs COGT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while COGT trades at $37.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas COGT's P/E ratio is -17.98. In terms of profitability, ACAD's ROE is +0.32%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ACAD is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check COGT's competition here
Erasca, Inc. (NASDAQ: ERAS)
ACAD vs ERAS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ERAS trades at $18.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ERAS's P/E ratio is -19.76. In terms of profitability, ACAD's ROE is +0.32%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ACAD is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ACAD vs SRRK Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while SRRK trades at $51.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas SRRK's P/E ratio is -15.22. In terms of profitability, ACAD's ROE is +0.32%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ACAD is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check SRRK's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ACAD vs CNTA Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ACAD's ROE is +0.32%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ACAD is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check CNTA's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ACAD vs CAI Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CAI has a market cap of 6.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CAI trades at $21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CAI's P/E ratio is 61.25. In terms of profitability, ACAD's ROE is +0.32%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ACAD is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check CAI's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ACAD vs MIRM Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MIRM trades at $100.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MIRM's P/E ratio is -6.92. In terms of profitability, ACAD's ROE is +0.32%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ACAD is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ACAD vs XENE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, XENE has a market cap of 6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while XENE trades at $62.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas XENE's P/E ratio is -13.27. In terms of profitability, ACAD's ROE is +0.32%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ACAD is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ACAD vs PTCT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while PTCT trades at $72.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas PTCT's P/E ratio is -30.77. In terms of profitability, ACAD's ROE is +0.32%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ACAD is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check PTCT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ACAD vs LGND Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while LGND trades at $294.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas LGND's P/E ratio is 32.34. In terms of profitability, ACAD's ROE is +0.32%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ACAD is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check LGND's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ACAD vs DFTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, DFTX has a market cap of 5.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while DFTX trades at $44.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas DFTX's P/E ratio is N/A. In terms of profitability, ACAD's ROE is +0.32%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ACAD is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ACAD vs TVTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while TVTX trades at $63.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas TVTX's P/E ratio is -138.09. In terms of profitability, ACAD's ROE is +0.32%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ACAD is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check TVTX's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ACAD vs CDTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ACAD's ROE is +0.32%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ACAD is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ACAD vs ABCM Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ACAD's ROE is +0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ACAD is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ACAD vs ISEE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ACAD's ROE is +0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ACAD is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ACAD vs APLS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas APLS's P/E ratio is 38.35. In terms of profitability, ACAD's ROE is +0.32%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ACAD is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ACAD vs CRSP Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CRSP trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CRSP's P/E ratio is -11.25. In terms of profitability, ACAD's ROE is +0.32%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ACAD is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check CRSP's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ACAD vs DYN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while DYN trades at $25.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas DYN's P/E ratio is -8.06. In terms of profitability, ACAD's ROE is +0.32%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ACAD is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ACAD vs TERN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas TERN's P/E ratio is -51.41. In terms of profitability, ACAD's ROE is +0.32%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ACAD is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ACAD vs EWTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while EWTX trades at $43.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas EWTX's P/E ratio is -23.88. In terms of profitability, ACAD's ROE is +0.32%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ACAD is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check EWTX's competition here
Veradermics, Incorporated (NYSE: MANE)
ACAD vs MANE Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MANE trades at $106.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MANE's P/E ratio is -35.90. In terms of profitability, ACAD's ROE is +0.32%, compared to MANE's ROE of -0.29%. Regarding short-term risk, ACAD is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ACAD vs FOLD Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ACAD's ROE is +0.32%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ACAD is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ACAD vs AKRO Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ACAD's ROE is +0.32%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ACAD is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check AKRO's competition here
Celcuity Inc. (NASDAQ: CELC)
ACAD vs CELC Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CELC trades at $91.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CELC's P/E ratio is -23.59. In terms of profitability, ACAD's ROE is +0.32%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ACAD is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check CELC's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ACAD vs ALPN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ACAD's ROE is +0.32%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ACAD is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check ALPN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ACAD vs RLAY Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RLAY trades at $20.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RLAY's P/E ratio is -12.65. In terms of profitability, ACAD's ROE is +0.32%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ACAD is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check RLAY's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ACAD vs PBLS Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while PBLS trades at $36.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas PBLS's P/E ratio is -42.12. In terms of profitability, ACAD's ROE is +0.32%, compared to PBLS's ROE of N/A. Regarding short-term risk, ACAD is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
ACAD vs OPT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas OPT's P/E ratio is -1.52. In terms of profitability, ACAD's ROE is +0.32%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ACAD is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ACAD vs PRTC Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ACAD's ROE is +0.32%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ACAD is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check PRTC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ACAD vs ELVN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ELVN trades at $58.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ELVN's P/E ratio is -35.22. In terms of profitability, ACAD's ROE is +0.32%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ACAD is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check ELVN's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ACAD vs TNGX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, TNGX has a market cap of 4.2B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while TNGX trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas TNGX's P/E ratio is -30.84. In terms of profitability, ACAD's ROE is +0.32%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ACAD is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check TNGX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ACAD vs MRTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ACAD's ROE is +0.32%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ACAD is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check MRTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ACAD vs TLX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while TLX trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas TLX's P/E ratio is -642.39. In terms of profitability, ACAD's ROE is +0.32%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ACAD is similarly volatile compared to TLX. This indicates similar risk in terms of short-term price fluctuations for ACAD.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ACAD vs ADPT Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while ADPT trades at $25.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas ADPT's P/E ratio is -60.34. In terms of profitability, ACAD's ROE is +0.32%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ACAD is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check ADPT's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ACAD vs DNLI Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while DNLI trades at $24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas DNLI's P/E ratio is -8.47. In terms of profitability, ACAD's ROE is +0.32%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, ACAD is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check DNLI's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ACAD vs VKTX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while VKTX trades at $33.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas VKTX's P/E ratio is -8.02. In terms of profitability, ACAD's ROE is +0.32%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ACAD is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check VKTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ACAD vs CPRX Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ACAD's ROE is +0.32%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ACAD is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check CPRX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ACAD vs LEGN Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while LEGN trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas LEGN's P/E ratio is -29.96. In terms of profitability, ACAD's ROE is +0.32%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ACAD is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ACAD.Check LEGN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ACAD vs RYZB Comparison August 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACAD stands at 4.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ACAD is priced at $28.74 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACAD currently has a P/E ratio of 13.71, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ACAD's ROE is +0.32%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ACAD is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ACAD.Check RYZB's competition here